Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
Article Title: A coiled coil-based pre-targeting drug delivery system for precise treatment of breast cancer.
doi: 10.1016/j.ejpb.2025.114794
Figure Lengend Snippet: Fig. 5. Specific cytotoxicity of pre-targeting complex. (a) Breast cancer cell lines were treated with increasing concentration (10, 20, 40, 80, 160, 320, 640 nM) of scFv-Zip2-Zip1-MMAE, scFv-Erbitux-MMAE, scFv-Sacit-MMAE, combination-Zip1-MMAE, scFv-Zip2-Zip1-SNAP, scFv-SNAP, combination-Zip1-SNAP, Zip1-MMAE or MMAE at 37 ◦C for 72 h, cell lines except SKBR3 were treated with increasing concentration (1.25, 2.5, 5, 10, 20, 40, 80, 160, 320, 640 nM) of scFv-Herceptin- MMAE. (b) SKBR3 was incubated with increasing concentration (0.03125, 0.0625, 0.125, 0.25, 0.5, 1, 2, 4, 8, 16 nM) of scFv-Herceptin-MMAE at 37 ◦C for 72 h. Cell viability was determined by XTT) Kit II, and the experiment was carried out in triplicates for three times. One independent experiment was shown with the mean ± SD.
Article Snippet: TNBC cell lines MDA-MB-468 (ACC 738), MDA-MB231 (ACC 732), MDA-MB-453 (ACC 65) and Hs578T (ACC 781), ER+ breast cancer cell line MCF7 (ACC 115), and Her2+ breast cancer cell lines SKBR3 (ACC 736) and BT474 (ACC 64) were purchased from the Leibniz Institute DSMZ.
Techniques: Concentration Assay, Incubation